These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 28823882)

  • 1. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
    Kim SR; Heaton H; Liu LY; King BA
    JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
    [No Abstract]   [Full Text] [Related]  

  • 3. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
    McKesey J; Pandya AG
    J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
    [No Abstract]   [Full Text] [Related]  

  • 5. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
    Olamiju B; Craiglow BG
    Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disorders of Hypopigmentation.
    Dina Y; McKesey J; Pandya AG
    J Drugs Dermatol; 2019 Mar; 18(3):s115-s116. PubMed ID: 30909355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
    Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
    An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
    Phan K; Phan S; Shumack S; Gupta M
    J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Systemic treatment of vitiligo : Balance and current developments].
    Meurer M; Ceric-Dehdari P
    Hautarzt; 2017 Nov; 68(11):876-884. PubMed ID: 29030646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
    Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
    [No Abstract]   [Full Text] [Related]  

  • 13. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.
    Tavakolpour S
    Dermatol Ther; 2018 Sep; 31(5):e12696. PubMed ID: 30207045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical and Maintenance Treatments for Vitiligo.
    Passeron T
    Dermatol Clin; 2017 Apr; 35(2):163-170. PubMed ID: 28317526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
    Yousefian F; Yadlapati S; Browning JC
    J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Lopes SR; Martins C; Teixeira M; Tomás D
    World J Gastroenterol; 2024 Sep; 30(34):3929-3931. PubMed ID: 39350781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
    Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
    Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
    Di Lernia V; Bardazzi F
    Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.